GlassScriptPhysician profile
Michael F Carter
NPI 1427045152
$9,397.79
in general payments reported to CMS, 2019-2025
39 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $1,800 · 2021: $1,388 · 2022: $1,295 · 2023: $1,057 · 2024: $1,255 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,882 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,881.95 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,751.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,011.23 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $933.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $754.06 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $641.09 | 2019-2022 | |
| Amgen INC. | $530.43 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $500.46 | 2019-2025 | Xifaxan |
| Organon LLC | $413.00 | 2022 | |
| Aytu Biopharma, INC. | $403.54 | 2020 | |
| Abbvie INC. | $368.41 | 2020-2023 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.01 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $340.36 | 2023-2025 | |
| Amarin Pharma, INC. | $275.37 | 2019-2021 | |
| Glaxosmithkline, LLC. | $243.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $144.69 | 2024-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $118.79 | 2019-2025 | Capvaxive, M-M-R II, Gardasil 9 |
| Exact Sciences Corporation | $103.98 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Tolmar, INC. | $61.62 | 2025 | Jatenzo |
| Allergan, INC. | $60.36 | 2019-2020 | |
| Antares Pharma, INC. | $48.83 | 2019 | |
| Abbott Laboratories | $45.73 | 2021-2022 | |
| Genentech USA, INC. | $45.20 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $42.55 | 2024 | |
| Lundbeck LLC | $33.86 | 2025 | Vyepti, Rexulti |
| Astellas Pharma US INC | $31.57 | 2023-2024 | Veozah |
| Inspire Medical Systems, INC. | $29.70 | 2025 | Inspire |
| Sanofi Pasteur INC. | $22.15 | 2025 | |
| Vanda Pharmaceuticals INC. | $16.89 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $16.58 | 2019 | |
| Currax Pharmaceuticals LLC | $15.58 | 2020 | |
| Bausch Health US, LLC | $12.27 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.12 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.22 | 2020 | |
| Adlon Therapeutics L.P. | $11.18 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.